A growing body of data suggests the importance of epigenetic mechanisms in cancer. Polycomb repressive complex 2 (PRC2) has been implicated in self-renewal and cancer progression, and its components are overexpressed in many cancers. However, its role in cancer development and progression remains unclear. We used conditional alleles for the PRC2 components enhancer of zeste 2 (Ezh2) and embryonic ectoderm development (Eed) to characterize the role of PRC2 function in leukemia development and progression. Compared with wild-type leukemia, Ezh2-null MLL-AF9-mediated acute myeloid leukemia (AML) failed to accelerate upon secondary transplantation. However, Ezh2-null leukemias maintained self-renewal up to the third round of transplantation, indicating that Ezh2 is not strictly required for MLL-AF9 AML, but plays a role in leukemia progression. Genome-wide analyses of PRC2-mediated trimethylation of histone 3 demonstrated locus-specific persistence of H3K27me3 despite inactivation of Ezh2, suggesting partial compensation by Ezh1. In contrast, inactivation of the essential PRC2 gene, Eed, led to complete ablation of PRC2 function, which was incompatible with leukemia growth. Gene expression array analyses indicated more profound gene expression changes in Eed-null compared with Ezh2-null leukemic cells, including down-regulation of Myc target genes and up-regulation of PRC2 targets. Manipulating PRC2 function may be of therapeutic benefit in AML. epigenetics | mouse model | polycomb group proteins | myeloid-lymphoid leukemia protein P olycomb repressive complex 2 (PRC2) has been implicated in development and cancer (1, 2) . PRC2 is composed of the core components embryonic ectoderm development (EED), suppressor of zeste 12 (SUZ12), and a SET-domain methyltransferase, either enhancer of zeste 2 (EZH2) or enhancer of zeste 1 (EZH1) (3) . The PRC2 complex catalyzes the di-and trimethylation of lysine residue 27 of histone 3 (H3K27me3), a repressive chromatin mark (4) . Overexpression of EZH2 has been correlated with prostate cancer progression (5) . Follow-up studies have confirmed and expanded these results for other cancer types, mainly solid tumors. In the hematopoietic system, forced expression of Ezh2 increases serial transplantation potential in hematopoietic stem cells (6) and enhances transformation in a model of multiple myeloma (7) . Intriguingly, heterozygous loss of function of EZH2 has been associated with adverse prognosis in myelofibrosis (8) , and heterozygous and homozygous inactivation of EZH2 has been described in myelodysplastic syndromes and more recently in Tlineage lymphoblastic leukemia (9) (10) (11) (12) . In contrast, EZH2 alterations appear to be rare events in acute myeloid leukemia (AML). How to reconcile these findings on a mechanistic level is unclear. Given the heterogeneity of clinical samples, elucidating the complex role of PRC2 biology in cancer will be aided by studies in genetically defined animal models (13) .
Loss of function of PRC2 has been evaluated in several cancer models (14, 15) . However, shRNA technologies used in these studies will leave in place some residual expression and function of the protein in question, obscuring the interpretation of experimental results. Furthermore, studies using shRNA can be plagued by off-target effects, especially when the readout is cellular toxicity. Here we describe studies evaluating loss of PRC2 function using conditional alleles, allowing for specific and complete deletion of individual PRC2 components. We conducted these studies in a well-defined mouse model of leukemia driven by the MLL-AF9 fusion oncoprotein.
We show that genetic inactivation of Ezh2 compromises but does not completely abrogate leukemia growth. Ezh2-inactivated MLL-AF9 leukemia shows persistence of H3K27me3 on many loci, suggesting compensation by Ezh1, as previously described in embryonic stem (ES) cells (16) . In contrast, complete genetic loss of PRC2-function by inactivation of Eed is incompatible with leukemic self-renewal. Our results demonstrate an absolute requirement for PRC2 function in MLL-AF9 AML and define a role for Ezh2 in cancer progression.
Results

Inactivation of Ezh2
Interferes with Growth of Preleukemic Colonies ex Vivo. We characterized the effects of genetic inactivation of PRC2 components in a defined model of AML. To this end, we used mice carrying three genetic modifications: (i) homozygously floxed sequences for either Ezh2 or Eed, (ii) polyI:polyC (pIpC)-inducible Cre (MxCre), and (iii) a Cre reporter, flox-STOP-flox-ROSA26-YFP (17) (Fig. S1A) . Initially, we studied the effects of loss of Ezh2 function in vitro. Lineage marker negative (Lin − ), c-Kit + , and Sca-1 + (LSK) immature progenitors and stem cells were purified by flow sorting, and cells were transduced with a bicistronic γ-retroviral vector encoding MLL-AF9 and linked via an internal ribosomal entry site (IRES), the reporter, GFP. Cells were transduced with a self-excising retroviral vector encoding Cre recombinase (18) . Cells double positive for GFP and YFP were sorted 6 d after Cre transduction and plated in methylcellulose. Ezh2-null cells showed a reduction in colony growth (Fig. S1B) , with smaller and scattered colonies (Fig.  S1C) . Cytospins of primary Ezh2-null colonies showed more differentiated morphology compared with WT counterparts (Fig.  S1C ). Attempts to replate Ezh2-null MLL-AF9 cells led to progressive outgrowth of cells with incompletely deleted Ezh2 sequences (as measured by qPCR, Fig. S1B ), suggesting a competitive disadvantage of Ezh2-null cells in vitro. These data demonstrate that inactivation of Ezh2 impairs leukemic colony formation ex vivo.
Ezh2-Null MLL-AF9 Leukemia Is Compromised but Maintains SelfRenewal Ability. We proceeded to study the in vivo effect of Ezh2 inactivation on MLL-AF9 leukemia. Blast colonies replated one to two times were derived from MLL-AF9-transduced LSK cells from Ezh2 flox/flox and WT mice. A total of 1 × 10 5 cells per recipient were i.v. injected into sublethally (600 cGy) irradiated primary recipient mice. Ezh2 flox/flox and WT donor mice also carried the MxCre and ROSA-YFP Cre-reporter alleles. pIpC was administered beginning 2-3 wk after transplantation. Two separate cohorts using MLL-AF9-transduced cells from two sets of donor mice were studied. Somewhat unexpectedly, given the impaired growth of Ezh2-null colonies in vitro, there was no apparent effect of Ezh2 inactivation on survival in primary recipients (Fig. 1A) . Leukemic mice typically had replacement of the bone marrow by leukemic cells of >90%, and spleens were consistently enlarged. Flow cytometry demonstrated that the majority of GFP + leukemia cells had excised the Cre reporter and had therefore also acquired YFP expression (Fig. S2A) . Western blot of sorted Ezh2-null GFP + /YFP + leukemic cells confirmed absence of Ezh2 protein and demonstrated substantially reduced, but detectable levels of H3K27me3 (Fig. 1B) . Near complete deletion of Ezh2 in leukemic cells from primary recipients was documented by qPCR ( Fig. S2B ) and by three-primer PCR (Fig. S2C ). Sorted GFP + /YFP + leukemic cells were transplanted into secondary recipients and three doses of pIpC were administered beginning 1 wk after transplantation to ensure full deletion of floxed sequences. In contrast to primary leukemia, there was a significant survival advantage in the Ezh2-null group (Fig. 1C) S2D ) and three-primer PCR (Fig. S2E ) demonstrated outgrowth of incompletely inactivated cells in one of four tested secondary recipients. We then performed tertiary transplantation of WT and Ezh2-null leukemia. As in secondary recipients, there was a significant survival advantage in the Ezh2-null group (Fig.  S3A ). Q-PCR (Fig. S3B ), Western blot (Fig. S3C) , and threeprimer PCR (Fig. S3D ) demonstrated outgrowth of incompletely Ezh2-inactivated cells in a proportion, but not all of the tested tertiary recipients. These data are consistent with a competitive survival disadvantage for Ezh2-null leukemic cells. However, the results also demonstrate that Ezh2 is not absolutely required for leukemia maintenance in the MLL-AF9 model, at least not until the third round of serial transplantation. The phenotype of Ezh2-null tertiary leukemia was compatible with AML as determined by flow cytometry (Fig. S3E) . Cell cycle analysis showed a modest but significant decrease in leukemic cells in S phase in Ezh2-null vs. WT leukemias in spleen ( Fig. 1D ) and bone marrow (Fig. S4 ). Given the cell cycle alterations in Ezh2-null cells, we evaluated the expression of known PRC2 targets, p16ink4a and p19arf, encoded by the Cdkn2a locus, by Western blot and found both gene products up-regulated in Ezh2-null leukemias ( Fig. 1 E and F). p16ink4a and p19arf are known tumor suppressors with roles in the Rb and p53 pathways, respectively, and it is likely that their up-regulation contributes to the phenotype observed after inactivation of Ezh2.
Expression Profiling of Ezh2-Null Leukemia Reveals a Functional Link
Between Gene Expression Programs Controlled by PRC2 and Myc. To better characterize the effects of Ezh2 deletion in MLL-AF9 leukemia on polycomb target genes, we performed gene expression profiling of primary and secondary WT and Ezh2-null leukemias. MLL-AF9 leukemia has been linked to an ES-celllike gene expression signature (19) . More recently, the ES-celllike signature often observed in cancer has been further subdivided into a PRC2 module, a Myc module, and a core ES module. These modules are defined by combinatorial DNA binding of Eed, Myc, and Nanog, and their associated factors (20) . Because we inactivated Ezh2, a PRC2 component, we tested enrichment of the PRC2 module by gene set enrichment analysis (GSEA) and found this signature to be significantly enriched in secondary Ezh2-null AML compared with secondary WT AML ( Fig. 2A) . Importantly, we found the Myc module genes to be significantly negatively enriched in Ezh2-null leukemic cells compared with WT counterparts (Fig. 2B ). WT and Ezh2-null tertiary leukemias showed similar degrees of infiltration of liver and spleen ( Fig. S5 ) but WT tertiary leukemias showed a more prominent infiltration of the kidney (Fig. 2C) . In contrast to the PRC2 and Myc modules, no significant negative or positive enrichment of the ES-cell core module signature was observed in Ezh2-null leukemic cells (Fig. S6A ). This finding is consistent with prior observations that the ES-cell core module may be of less importance in cancers. Inactivation of Ezh2 also did not result in enrichment of primary MLL-AF9 binding targets, as is observed, e.g., after inactivation of the histone methyltransferase, Dot1l (21) (Fig. S6B ). The gene sets used are listed in Dataset S1.
Decreased Myc expression has been demonstrated after loss of function of another epigenetic regulator implied in MLL-AF9 leukemia, namely, Brd4 (22) (23) (24) . However, despite significant attenuation of the Myc module, inactivation of Ezh2 in our system did not lead to altered Myc protein levels by Western blot (Fig. 2D ), or mRNA levels by qPCR (relative expression Ezh2/ WT = 1). These data suggest an indirect mechanism for the observed down-regulation of Myc module genes. It is noteworthy that PRC2 components have recently been shown to be direct downstream targets of Myc (25) . Our genome-wide expression profiling data suggest that the expression of Myc target genes is partly dependent on PRC2, a functional link between PRC2 and Myc module gene expression that had not been previously noted.
Progression of WT MLL-AF9 Correlates with Down-Regulation of PRC2
Module Genes and Depends on Ezh2. Analysis of survival curves shows a progression from primary WT leukemia to secondary and tertiary leukemia, as manifested by a significantly shortened latency (Fig. S7A ). This shortened latency was not observed in the Ezh2-null setting (Fig. S7B) . We compared expression profiles of primary and secondary WT and Ezh2-null leukemias. Progression from primary to secondary WT leukemia correlated with repression of PRC2 module genes (Fig. S7C ) and increase of Myc module genes (Fig. S7E) . In contrast, and in keeping with the comparable latency of primary and secondary/tertiary AML in the Ezh2-null background, there was no significant negative enrichment of the PRC2 module (Fig. S7D ) and no enrichment of the Myc module (Fig. S7F ) observed between Ezh2-null secondary and Ezh2-null primary leukemia. In summary, these data illustrate that Ezh2 is required for leukemia progression to a more aggressive disease with shortened latency, an increased fraction of actively cycling leukemic cells, and increased organ infiltration. However, because Ezh2-null cells gave rise to leukemia even in tertiary recipients, the data also demonstrate that Ezh2 is not strictly required for AML development and self-renewal.
Genome-Wide H3K27me3 Analysis in Ezh2-Null Leukemic Cells Demonstrates Protection from Loss of H3K27me3 on Loci Encoding
Developmental Regulators. Studies in ES cells have revealed that the inactivation of Eed leads to complete loss of H3K27me3, whereas inactivation of Ezh2 leads to substantial but incomplete loss of H3K27me3 and a more moderate disturbance in phenotype, owing to partial compensation by Ezh1 (16). To further characterize the effects of Ezh2 inactivation in AML, we analyzed the H3K27me3 pattern for WT and Ezh2-null leukemic cells. To this end, we performed chromatin immunoprecipitation followed by next generation sequencing (ChIP-Seq) on sorted GFP + /YFP + double positive leukemic cells from primary and secondary AML. Among the polycomb targets, we found genes (termed "class 1") with loss of H3K27me3 upon Ezh2 inactivation, and polycomb target genes with persistent H3K27me3 despite efficient Ezh2 inactivation (termed "class 2" genes) (Fig.  3A) . A class 1 gene set for GSEA was defined as a group of genes with significant H3K27me3 (P < 0.01) in wild-type cells and threefold or greater loss of signal at corresponding loci in Ezh2-null leukemic cells. A class 2 gene set was defined as containing genes with significant H3K27me3 (P < 0.001) in Ezh2-null leukemic cells and no decrease in H3K27me3 signal compared with the corresponding loci in WT leukemic cells. The gene sets used are listed in Dataset S2.
The expression of class 1 genes is enriched in Ezh2-null leukemic cells compared with WT counterparts as assessed by GSEA (Fig. 3B) . This indicates preferential derepression of polycomb target loci showing loss of H3K27me3 after Ezh2 inactivation. Akin to the situation previously characterized in Ezh2-null ES cells (16), we found a group of class 2 genes in MLL-AF9 leukemic cells (Dataset S2) with substantial levels of protected H3K27me3 despite Ezh2 inactivation. These genes are not significantly enriched in Ezh2-null or WT leukemia (Fig. 3B) . The class 2 gene set contains many DNA-binding proteins such as Hox-genes, distal-less homeobox genes, paired-box genes, and Gata factors. Using gene-set overlap analysis of this gene set with Gene Ontology gene sets from the Molecular Signatures Database (MsigDB) revealed the most significant overlap with annotations with a role in development, such as "Anatomical Structure Development," "Transcription Factor Activity," "DNA Binding," and "System Development" (Dataset S2).
The preferential activity of the Ezh1-containing PRC2 to developmental regulators is therefore not only observed in ES cells (16) but is also encountered in leukemia. We compared the genes found to be marked by H3K27me3 in Ezh2-null leukemias with data obtained using Ezh2-null murine ES cells. There is highly significant overlap between protected loci in Ezh2-leukemic cells and loci both H3K27me3 modified and bound by Ezh1 in Ezh2-null murine ES cells. These data support the concept that Ezh1, the only other H3K27 trimethylase besides Ezh2, partially compensates for the inactivation of Ezh2 in our MLL-AF9 leukemia model (Fig. 3C ).
Complete Loss of PRC2 Function Is Incompatible with MLL-AF9
Leukemia. The relatively mild in vivo phenotype of Ezh2 inactivation in MLL-AF9 leukemia was somewhat unexpected. We therefore evaluated the consequences of complete abrogation of PRC2 function. To this end, we used a murine model with floxed sequences of the essential PRC2 component, Eed. We studied the effect of inactivation of Eed on the maintenance of established leukemia (Fig. 4 A and B) . Survival of mice in the Eed flox/flox group was significantly prolonged compared with recipients of WT cells (Fig. 4B) . Flow cytometric analysis demonstrated consistent outgrowth of GFP single positive cells that had failed to undergo deletion of floxed sequences (Fig. 4C) . We aimed to further characterize the effect of Eed inactivation on MLL-AF9 transduced cells. pIpC was administered to primary recipients of Eed flox/flox and WT MLL-AF9-transduced LSK-derived colonies and mice were killed 3 or 8 d after the last dose of pIpC. GFP + / YFP + double positive cells were sorted and analyzed. Deletion of Eed sequences was functionally assessed by Western blot for H3K27me3. Undetectable levels of H3K27me3 were documented in three mice (Fig. 4D) . Sorted GFP + /YFP + cells from two of these mice had minimal residual WT Eed signal by PCR (Fig.  S8A ) and by qPCR (1.2 and 0.7%). In contrast, all mice assayed 8 d after the last dose of pIpC demonstrated only slightly reduced levels of H3K27me3, consistent with rapid outgrowth of cells that retain PRC2 function (Fig. 4D) . PCR analysis showed bands for the floxed and the inactivated allele, suggesting outgrowth of cells with heterozygous deletion of floxed Eed sequences (Fig. S8B) . The phenotype of fully Eed-inactivated leukemias was consistent with AML (Fig. S8C) . To evaluate the capability of Eed-null cells to form leukemia in a noncompetitive setting, we injected sorted GFP + /YFP + leukemic cells with minimal detectable levels of H3K27me3 and minimal qPCR signal for WT Eed sequences into secondary recipients (Fig. S9A) . Recipients of Eed-null cells showed a significant survival advantage. Four of six recipients of Eed-null cells developed leukemia eventually. However, leukemic mice demonstrated outgrowth of incompletely inactivated cells (Fig. S9B) . We went on to test whether we could demonstrate successful early engraftment of Eed-null cells in secondary recipients, injecting 1 × 10 6 sorted live cells per recipient. Whereas WT cells showed clear engraftment 18 h, 1 wk, and 1 mo after transplantation, very few Eed-null cells engrafted and these cells expanded poorly in vivo (Fig. 5A) . Of note, very few Eed-null cells were detected in the bone marrow even at 18 h, suggesting not only a proliferative block but also a homing or survival effect of Eed-null leukemic cells in vivo. The maximal engraftment observed in the Eed-null group was 0.2% in one mouse 1 mo after transplantation. However, when sorted and subjected to PCR analysis, these cells were determined to be escapees that had failed to excise one of the floxed alleles (Fig. S9C ).
Complete Loss of PRC2 Function Accentuates Gene Expression Changes
Compared with Loss of Ezh2. We performed gene expression profiling on Eed-null leukemias with minimal residual WT sequences as assessed by qPCR. Comparing Eed-null to Ezh2-null leukemias (Fig. S10) , gene set enrichment analysis demonstrated positive enrichment of the PRC2 (Fig. S10A ) module and significant negative enrichment of the Myc module (Fig. S10B) . Similar to the situation after inactivation of Ezh2, decreased expression of the ES-cell core module was not observed in Eed-null cells (Fig.  S10C) . Interestingly, primary MLL-AF9 targets were negatively enriched in Eed-null leukemia compared with Ezh2-null leukemia (Fig. S10D) . Myc protein levels were not decreased in Eed-null leukemias compared with WT (Fig. S10E) . Western blot analysis demonstrated up-regulation of p16ink4a and p19arf in fully Eednull primary AML in vivo (Fig. 5B) . We then compared derepression of p16ink4a and p19arf side by side in vitro in WT, Ezh2-null, and Eed-null cells, 6 d after deletion mediated by transduction with a self-excising Cre-encoding vector. Western blot demonstrates a more pronounced derepression of Cdkn2a gene products after inactivation of Eed, especially in the case of p19arf (Fig. 5C) . Finally, we wanted to analyze the expression of class 2 genes, which retain significant H3K27me3 in Ezh2-null leukemia and are not enriched in Ezh2-null compared with WT leukemia. This gene set is highly significantly enriched in Eed-null AML compared with Ezh2-null leukemia (Fig. 5D) . In summary, inactivation of Eed leads to complete loss of PRC2 function and complete loss of H3K27me3. This loss is accompanied by derepression of polycomb targets silenced by persistent H3K27me3 in Ezh2-null leukemic cells and by attenuated expression of a Myc module with documented importance in cancer. These gene expression changes are accompanied by failure of Eed-null leukemic cells to proliferate in vivo, demonstrating that in contrast to murine ES cells (16, 26) and murine epidermis (27) , MLL-AF9 leukemia strictly depends on PRC2 function.
Discussion
Conflicting data exist regarding the role of PRC2 in cancer. Elevated levels of PRC2 components have been shown to be associated with aggressiveness, invasiveness, and survival in solid tumors (5) . A gain-of-function mutation for EZH2 has been described in large cell lymphoma (28) . On the other hand, heterozygous and homozygous mutation and/or deletion of EZH2 has been described in some hematologic malignancies (8) (9) (10) (11) (12) 29) , but is not typically seen in AML. Understanding of PRC2 biology in cancer is limited by the heterogeneity of clinical samples and the pleiotropy of genetic programs controlled by PRC2. We here present data using a genetically defined murine model to study the effects of homozygous inactivation of genes encoding the PRC2 components Ezh2 and Eed on MLL-AF9 leukemia.
Ezh2 Is Not Strictly Required for MLL-AF9 AML. A requirement for Ezh2 in malignant self-renewal in murine cancer models has been suggested, either using shRNA approaches (14) or genetically engineered ablation (30) . In contrast, we provide evidence that Ezh2 is not strictly required for MLL-AF9 leukemia, as we were able to derive Ezh2-null MLL-AF9 AML up to the third round of serial transplantation. The Ezh2-null leukemias have a lower proportion of actively cycling cells and a lesser degree of organ infiltration. WT leukemia but not Ezh2-null leukemias show significant acceleration upon transplantation from primary into secondary recipients, which is accompanied by transcriptional down-regulation of polycomb targets and up-regulation of Myc targets. There is no shortened latency in the secondary and tertiary Ezh2-null MLL-AF9 leukemias, and the enrichment of Myc and PRC2 modules were absent in secondary compared with primary Ezh2-null leukemia. These data show that Ezh2 is required for tumor progression in the MLL-AF9 model. Importantly and in contrast to the data presented here, Ezh2 using a conditional knockout model was shown to be essential for lymphomagenesis induced by inactivation of Snf5 (30) . This discrepancy demonstrates the importance of context for the role epigenetic modifiers play in cancer. Future studies will correlate the data presented here with data from human leukemia (e.g., at diagnosis and at relapse).
Ezh2-Null Cells Retain Significant H3K27me3. Inactivation of Ezh2 can be partially compensated in ES cells, where the inactivation of Ezh2 is associated with milder functional defects than the inactivation of Eed (16) . Recently, it has been suggested that in normal hematopoiesis, Ezh1 compensates for inactivation of Ezh2 in adult but not fetal cells (31) . In murine MLL-AF9 leukemia, we found a significant number of genes in which H3K27me3 is retained after Ezh2 inactivation. There is large overlap in the set of genes that retain H3K27me3 between ES cells and AML leukemic cells, and almost all of these genes are documented Ezh1 targets. Ezh1 is the only other known methyltransferase besides Ezh2 to catalyze the trimethylation of H3K27 (16, 32) . The ability of Ezh1 to compensate for Ezh2 inactivation in cancer appears to be context dependent (30) . Little is currently known about the composition and recruitment of PRC2-Ezh1 in cancer. Our data suggest a role for Ezh1 in MLL-AF9 leukemia that will need to be addressed in more detail in future studies.
Eed Is Absolutely Required for MLL-AF9 Leukemia. We evaluated the response of MLL-AF9 leukemia to complete loss of PRC2 function by inactivation of the essential component, Eed. This is accompanied by more profound gene-expression changes than after inactivation of Ezh2. Specifically, a subset of genes retaining highly significant H3K27me3 after inactivation of Ezh2 is derepressed after inactivation of Eed, but not after inactivation of Ezh2. Complete loss of PRC2 function after inactivation of Eed is incompatible with leukemia growth. This is in contrast to ES cells and the early embryo, where growth after complete loss of PRC2 function is compromised, but not abolished (16, 26, 33) . PRC2 function has also been shown to be dispensable for proliferation of Ezh1/Ezh2 double-knockout cells in the epidermis proper but required in the hair follicle (27) . In summary, available data illustrate that the consequences of partial and complete loss of PRC2 function are context dependent.
It is noteworthy that two transcriptional modules derived from the study of ES cells (20) are found in a leukemia model, and that they appear functionally linked. Our data suggest that modulation of polycomb function may be a strategy to therapeutically decrease expression of Myc transcriptional targets, at least in MLL-AF9 leukemia. In this respect it is reassuring that Ezh2 does not appear required for adult normal hematopoietic stem cell function (31) . There is little doubt that a cure for MLL-AF9 AML will require combination therapies. The model described here will allow us to further study pathways that collaborate with PRC2 in the maintenance of MLL-rearranged leukemia, with the goal of defining combinations of critical drug targets and of eventually developing rational drug combinations to better treat MLL-AF9 AML. (Fig. 3B ) but is derepressed and significantly enriched in Eed-null vs. Ezh2-null leukemic cells.
Materials and Methods
For antibodies and detailed experimental procedures, please refer to SI Materials and Methods.
Mice and Breeding. Animals were maintained at the animal research facility at Children's Hospital Boston. Animal experiments were approved by the institutional animal care and use committee. Conditional mice were maintained on a C57B/6 background crossed to MxCre and ROSA26-flox-STOPflox-EYFP mice.
Generation of Transformed Murine Cells and Leukemia. Ecotropic retroviral vectors were generated by cotransfection of 293T cells with packaging constructs. LSK cells were transduced with MLL-AF9-GFP and maintained in methylcellulose with supplemental cytokines. In some experiments, cells were then transduced with hit-and-run Cre and 5-6 d later, GFP + /YFP + cells were sorted and plated. Replated colonies were transplanted into C57B/6 syngeneic sublethally irradiated (600 rad) recipients at 1-2 × 10 5 cells per mouse. For secondary transplants, GFP + /YFP + sorted cells from leukemic mice were transplanted.
Biochemical Assays: Cell Growth, Apoptosis, Cell Cycle Analysis, Western Blotting, and qPCR. Cell cycle analysis was performed using the BrdU-APC/ 7AAD kit from BD PharMingen. BrdU was administered i.p. to leukemic mice and mice were killed and analyzed 1 h later. Antibodies used are detailed in SI Materials and Methods. For colony assays, sorted transduced leukemia cells were plated in methylcellulose M3234 (Stem Cell Technologies) containing IL3, IL6, and murine stem cell factor (mSCF) at 1,000-5,000 cells per plate, and replated every 5-7 d. In some experiments, GFP + /YFP + were sorted before the first and second platings.
ChIP-qPCR and ChIP-Seq. GFP + /YFP + leukemic cells were isolated by FACS sorting. For ChIP of H3K27me3, ChIP was performed as previously described (34), using a polyclonal rabbit antibody (Millipore; 07449) specific to the modification. Briefly, cross-linking was performed with 1% formalin, and the cells were lysed in SDS buffer. DNA was fragmented by sonication and histones and bound DNA were precipitated overnight. Eluted DNA fragments were analyzed by qPCR or subjected to sequencing using next-generation Solexa sequencing. org/cancer/software/genepattern/), and the probe sets were mapped to genes using library files (version 30) downloaded from the Affymetrix Website. GSEA was performed using www.broadinstitute.org/gsea. The integrative analysis of histone modification levels and gene expression was performed using iCanPlot. Statistical tests were performed using GraphPad Prism5; for details see SI Materials and Methods.
RNA Amplification and Gene Expression
